Paediatric Psoriasis

Dosing with Enbrel^® can be individualised based on the needs of each patient.¹
The recommended dose of Enbrel^® for paediatric patients with plaque PsO is based on weight¹:

• 0.8 mg/kg (up to a maximum of 50 mg per dose) QW for up to 24 weeks

Treatment should be discontinued in paediatric patients with PsO who show no response after 12 weeks. If re-treatment with Enbrel^® is indicated, the above guidance on dosage and treatment duration should be followed.¹

Enbrel^® Significantly Improves Clinical Outcomes in Pediatric Patients With Plaque PsO^2,3

Enbrel^® Improves the severity of plaque PsO in children and adolescents as early as Week 2.²

Adapted from Paller AS, et al. 2008.

Paller AS. 2008. Methods: In this 48-week study, 211 patients with PsO (4-17 years of age) were initially randomly assigned to a double-blind trial of 12 QW subcutaneous injections of placebo or 0.8 mg of etanercept per kilogram of body weight (to a maximum of 50 mg), followed by 24 weeks of QW open-label etanercept. At Week 36, 138 patients underwent a second randomisation to placebo or etanercept to investigate the effects of withdrawal and retreatment. The primary endpoint was 75% or greater improvement from baseline in the PASI 75 at Week 12. Secondary endpoints included PASI 50, PASI 90, PGA of clear or almost clear of disease and safety assessments.

Enbrel^® Helps Paediatric Patients With Plaque PsO Achieve Sustained Clinical Response³

PASI 50, PASI 75* and PASI* 90 responses compared with baseline throughout first 96 weeks of extension study (observed cases)³

Adapted from Paller AS, et al. 2010.

Paller AS. 2010: Methods: Patients who completed or received substantial treatment benefit in a 48-week, randomised, double-blind, placebo-controlled study (N=211) evaluating the efficacy and safety of QW etanercept (0.8 mg/kg) were enrolled in this 264-week OLE study.²

The primary endpoint was the occurrence of AEs. Secondary endpoints included PASI 50%, 75% and 90% responses compared with baseline; static PGA; and clear and clear/almost clear static PGA status. Results from a 96-week interim analysis are presented.²

PASI 75* at Week 96 (61%) was similar to the report at Week 12 for patients initially randomised to Enbrel^® in the Paller clinical trial (57%)³

*Improvements in PASI 75, 50 and 90 over baseline in PASI.³

AE, adverse event; OLE, open-label extension; PASI, Psoriasis Area and Severity Index; PGA, physician global assessment; PsO, psoriasis; QW, once a week; TNFR, tumour necrosis factor receptor.

References: